» Articles » PMID: 28973968

The Role and Mechanism of Epithelial-to-Mesenchymal Transition in Prostate Cancer Progression

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2017 Oct 5
PMID 28973968
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

In prostate cancer (PCa), similar to many other cancers, distant organ metastasis symbolizes the beginning of the end disease, which eventually leads to cancer death. Many mechanisms have been identified in this process that can be rationalized into targeted therapy. Among them, epithelial-to-mesenchymal transition (EMT) is originally characterized as a critical step for cell trans-differentiation during embryo development and now recognized in promoting cancer cells invasiveness because of high mobility and migratory abilities of mesenchymal cells once converted from carcinoma cells. Nevertheless, the underlying pathways leading to EMT appear to be very diverse in different cancer types, which certainly represent a challenge for developing effective intervention. In this article, we have carefully reviewed the key factors involved in EMT of PCa with clinical correlation in hope to facilitate the development of new therapeutic strategy that is expected to reduce the disease mortality.

Citing Articles

MicroRNA-875-5p inhibits the growth and metastasis of cervical cancer cells by promoting autophagy and apoptosis and inhibiting the epithelial-mesenchymal transition.

Liang Y, Li C, Hou X, Lin Y, Cheng J Front Oncol. 2024; 14:1361721.

PMID: 38800376 PMC: 11116804. DOI: 10.3389/fonc.2024.1361721.


Circular RNAs in EMT-driven metastasis regulation: modulation of cancer cell plasticity, tumorigenesis and therapy resistance.

Ashrafizadeh M, Dai J, Torabian P, Nabavi N, Aref A, Aljabali A Cell Mol Life Sci. 2024; 81(1):214.

PMID: 38733529 PMC: 11088560. DOI: 10.1007/s00018-024-05236-w.


Novel role of LLGL2 silencing in autophagy: reversing epithelial-mesenchymal transition in prostate cancer.

Hong G, Kim K, Kim Y, Lee H, Cho S, Han S Biol Res. 2024; 57(1):25.

PMID: 38720397 PMC: 11077766. DOI: 10.1186/s40659-024-00499-w.


Unveiling the potential of SLURP1 protein as a biomarker for prostate cancer screening.

Yang T, Liu T, Lei T, Li T, Liu N, Zhang M Front Oncol. 2024; 14:1365615.

PMID: 38686195 PMC: 11057230. DOI: 10.3389/fonc.2024.1365615.


NEAT1 promotes the progression of prostate cancer by targeting the miR-582-5p/EZH2 regulatory axis.

Xu W, Wu Y, Zhang G Cytotechnology. 2024; 76(2):231-246.

PMID: 38495291 PMC: 10940559. DOI: 10.1007/s10616-023-00612-z.


References
1.
Kong D, Li Y, Wang Z, Banerjee S, Ahmad A, Kim H . miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells. 2009; 27(8):1712-21. PMC: 3400149. DOI: 10.1002/stem.101. View

2.
Chen X, Liu Z, Zhang G, Wei W, Wang X, Wang H . TGF-β and EGF induced HLA-I downregulation is associated with epithelial-mesenchymal transition (EMT) through upregulation of snail in prostate cancer cells. Mol Immunol. 2015; 65(1):34-42. DOI: 10.1016/j.molimm.2014.12.017. View

3.
Jin Y, Cui Z, Li X, Jin X, Peng J . Upregulation of long non-coding RNA PlncRNA-1 promotes proliferation and induces epithelial-mesenchymal transition in prostate cancer. Oncotarget. 2017; 8(16):26090-26099. PMC: 5432240. DOI: 10.18632/oncotarget.15318. View

4.
Ibrahim A, Weirauch U, Thomas M, Grunweller A, Hartmann R, Aigner A . MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res. 2011; 71(15):5214-24. DOI: 10.1158/0008-5472.CAN-10-4645. View

5.
Liu C, Guan H, Wang Y, Chen M, Xu B, Zhang L . miR-195 Inhibits EMT by Targeting FGF2 in Prostate Cancer Cells. PLoS One. 2015; 10(12):e0144073. PMC: 4674136. DOI: 10.1371/journal.pone.0144073. View